Sign in to view content

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2024

Related

Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Efficacy and Safety of Anti-High Temperature Requirement A1 aHtrA1 Fab in Geographic Atrophy GA Secondary to AMD GAllego Phase 2 Randomized Trial
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2023
Development of a Novel Retinal Tamponade Agent to Replace Fluorinated Gas and Silicone Oil
James A Stefater, MD, PhD
Annual Meeting Talks
2019

Category: Hereditary Retinal Disease & Genetics

See more